Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We recently reported that two of six HLA-DP supertypes (DP1-4, 6, 8) were associated with susceptibility (DP2) and resistance (DP1) to childhood acute lymphoblastic leukaemia (ALL). To determine whether DP supertypes are associated with childhood ALL prognosis, we compared treatment outcomes in a cohort (n = 798) of DPB1-typed ALL cases in the UK Medical Research Council UKALL XI trial. No differences in clinical characteristics and outcome between DPB1-typed and untyped (n = 1292) cases suggest no selection bias. Event-free survival (EFS) rates in patients with DP1 and DP3 supertypes were significantly worse than in patients with DP2, DP4, DP6 and DP8 [10-year EFS: 55%; 95% confidence interval (CI) = 49-61%; compared with 64% (61-68%), P = 0.006]. Ten-year EFS in DP1/DP3 heterozygous patients [30% (2-58%)] was significantly worse than in patients with DP1, DP3 or neither allele [56% (50-62%); P = 0.02]. Lack of evidence that DP1 or DP3 are associated with known prognostic factors leads us to suggest that these two supertypes exert an independent effect on prognosis. This may involve abrogation of DP1/3-restricted T-cell control of residual disease due to selective effects of chemotherapy. Further studies of HLA supertypes in relation to outcome in recent childhood ALL trials may resolve this question.

Original publication

DOI

10.1111/j.1365-2141.2008.07571.x

Type

Journal article

Journal

Br J Haematol

Publication Date

04/2009

Volume

145

Pages

87 - 95

Keywords

Adolescent, Biomarkers, Tumor, Chi-Square Distribution, Child, Child, Preschool, Disease-Free Survival, Female, Genetic Predisposition to Disease, Genotype, HLA-DP Antigens, HLA-DP beta-Chains, Humans, Immunosuppressive Agents, Infant, Kaplan-Meier Estimate, Male, Methotrexate, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Randomized Controlled Trials as Topic, Statistics, Nonparametric, Treatment Outcome